OLX-301A is under clinical development by Laboratoires Thea and currently in Phase I for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase I drugs for Wet (Neovascular / Exudative) Macular Degeneration have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OLX-301A’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OLX-301A overview

OLX-301A is under development for the treatment of wet and dry macular degeneration and geography atrophy. The drug candidate is administered by intraocular route. It is an antisense RNAi oligonucleotide based on the cp-lasiRNA technology. It was also under development for the treatment of diabetic macular edema (DME)

Laboratoires Thea overview

Laboratoires Thea (Thea) is pharmaceutical company that researches, develops, manufactures, and commercializes a wide variety of eye care products. The company’s products find application in the diagnosis, surgery and treatment of ophthalmic diseases such as dry eye, allergies, glaucoma, ocular and eyelid hygiene, eye surgery, and violations of the posterior segment. Its product portfolio includes eye drops, ophthalmic gels, sterile compresses and micellar solutions. Thea markets these products under the brand names Blephagel, Blephasteam, Nutrof, ABAK, Blephasol, and Blephaclean. The company markets products through sales organizations and distributors. Thea is headquartered in Clermont Ferrand, Auvergne, France.

For a complete picture of OLX-301A’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.